LYLA (previously AlphaPace) is a spin-off company from Delft University of Technology and Erasmus MC, with support from Delft Enterprises B.V., TU Delft | Reactor Institute, and all others that helped to turn pioneering research from TU Delft and Erasmus MC into an impactful solution for cancer diagnostics and treatment.
LYLA’s flagship product includes a test to assess the safety and quality of radioactive isotopes used in promising new cancer treatments. Within minutes, LYLA facilitates the thorough evaluation of Targeted Radionuclide Therapy, resulting in time and cost savings, while also enhancing the efficacy of these medicines in the battle against cancer.
LYLA’s team (Kas Hogeboom, Ernst van der Wal, Bauke van Gameren, Jeroen Plomp, Antonia Denkova, Erik de Blois) is a blend of professionals, each bringing unique expertise to the table. From clinical research to innovative technical solutions and strategic business insights, all together creating the driving force behind the company's ambition to push the boundaries and introducing innovative solutions in cancer treatment.
We are proud to highlight the contribution of Dr. Erik de Blois, a clinical radiochemist and head of quality control at Erasmus MC who’s research on radioactive isotopes is pivotal for the clinical implementation of radiopharmaceuticals in cancer treatment.
In 2024 LYLA’s quality test proudly won the Philips Innovation Award in the Rough Diamond category, selected from 175 entries. This recognition highlights the innovative contribution to advancing healthcare and radiopharmaceutical quality testing.
Technology Transfer Office wishes LYLA team a smooth and successful business journey!
Follow LYLA on LinkedIN or visit company’s website for more details.
